Browsing Tag
Malignant Fungating Wounds
1 post
Vyome clears final Phase 2 hurdle for VT-1953, sets stage for pivotal FDA trial in high-need cancer care
Vyome advances VT-1953 toward pivotal FDA trials after strong Phase 2 results in malignant fungating wounds. Discover the regulatory and market impact.